Needham & Company LLC Lowers Artivion (NYSE:AORT) Price Target to $32.00

Artivion (NYSE:AORT) had its target price dropped by equities researchers at Needham & Company LLC from $34.00 to $32.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 25.79% from the stock’s current price.

Several other research analysts also recently commented on AORT. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Oppenheimer raised their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Stock Down 0.5 %

AORT stock opened at $25.44 on Tuesday. Artivion has a fifty-two week low of $18.38 and a fifty-two week high of $32.33. The business’s 50-day moving average is $29.68 and its two-hundred day moving average is $27.83. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -1,272.00 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. As a group, analysts forecast that Artivion will post 0.37 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Lance A. Berry sold 3,259 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the sale, the chief financial officer now owns 75,805 shares in the company, valued at approximately $2,070,234.55. This trade represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 77,224 shares of company stock worth $2,162,330. 8.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Wasatch Advisors LP grew its holdings in Artivion by 27.7% during the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after buying an additional 226,160 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in Artivion during the 3rd quarter valued at approximately $5,798,000. Point72 Asset Management L.P. purchased a new position in Artivion during the 4th quarter valued at approximately $5,573,000. First Trust Advisors LP purchased a new position in Artivion during the 4th quarter valued at approximately $4,771,000. Finally, Tidal Investments LLC grew its holdings in Artivion by 602.2% during the 3rd quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after buying an additional 134,642 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.